Sarepta Signs a Two-Year Research and Option Agreement with Codiak for Up to Five Neuromuscular Targets

 Sarepta Signs a Two-Year Research and Option Agreement with Codiak for Up to Five Neuromuscular Targets

Sarepta Signs a Two-Year Research and Option Agreement with Codiak for Up to Five Neuromuscular Targets

Shots:

  • Codiak to receive up to $72.5M upfront, near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future sales of therapies emerges during the collaboration
  • Sarepta gets an exclusive option to license Codiak’s technology to develop and commercialize engineered exosome therapies for up to five neuromuscular targets. Following exercising of an option, Codiak will be responsible for research and preclinical development through IND preparation while Sarepta will lead clinical development and commercial activities
  • The collaboration will leverage Codiak’s exosome engineering capabilities with Sarepta’s expertise in precision genetic medicine to develop next-generation therapeutics targeting the needs of patients with neuromuscular diseases

Click here to read full press release/ article | Ref: Sarepta Therapeutics | Image: STAT

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post